John G. Ullman & Associates’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $703K | Sell |
910
-920
| -50% | -$704K | 0.09% | 118 |
|
|
2025
Q4 | $1.41M | Sell |
1,830
-125
| -6% | -$84.9K | 0.19% | 92 |
|
|
2025
Q3 | $1.1M | Buy |
1,955
+550
| +39% | +$311K | 0.15% | 94 |
|
|
2025
Q2 | $738K | Sell |
1,405
-5,025
| -78% | -$2.8M | 0.11% | 108 |
|
|
2025
Q1 | $4.08M | Buy |
6,430
+3,115
| +94% | +$2.14M | 0.63% | 52 |
|
|
2024
Q4 | $2.36M | Buy |
+3,315
| New | +$2.78M | 0.35% | 80 |
|
|
2023
Q1 | – | Sell |
-4,260
| Closed | -$3.07M | – | 181 |
|
|
2022
Q4 | $3.07M | Sell |
4,260
-130
| -3% | -$95.9K | 0.49% | 54 |
|
|
2022
Q3 | $3.02M | Sell |
4,390
-60
| -1% | -$37.8K | 0.53% | 52 |
|
|
2022
Q2 | $2.63M | Buy |
4,450
+3,650
| +456% | +$2.37M | 0.42% | 62 |
|
|
2022
Q1 | $559K | Hold |
800
| – | – | 0.08% | 117 |
|
|
2021
Q4 | $505K | Hold |
800
| – | – | 0.07% | 118 |
|
|
2021
Q3 | $484K | Hold |
800
| – | – | 0.07% | 117 |
|
|
2021
Q2 | $447K | Hold |
800
| – | – | 0.06% | 121 |
|
|
2021
Q1 | $379K | Hold |
800
| – | – | 0.05% | 121 |
|
|
2020
Q4 | $386K | Hold |
800
| – | – | 0.06% | 115 |
|
|
2020
Q3 | $448K | Hold |
800
| – | – | 0.09% | 84 |
|
|
2020
Q2 | $499K | Hold |
800
| – | – | 0.12% | 68 |
|
|
2020
Q1 | $391K | Hold |
800
| – | – | 0.1% | 80 |
|
|
2019
Q4 | $300K | Sell |
800
-25
| -3% | -$8.41K | 0.05% | 122 |
|
|
2019
Q3 | $229K | Sell |
825
-75
| -8% | -$22.2K | 0.04% | 134 |
|
|
2019
Q2 | $282K | Hold |
900
| – | – | 0.05% | 126 |
|
|
2019
Q1 | $370K | Hold |
900
| – | – | 0.07% | 101 |
|
|
2018
Q4 | $336K | Hold |
900
| – | – | 0.07% | 102 |
|
|
2018
Q3 | $364K | Hold |
900
| – | – | 0.07% | 103 |
|
|
2018
Q2 | $310K | Hold |
900
| – | – | 0.06% | 97 |
|
|
2018
Q1 | $310K | Hold |
900
| – | – | 0.06% | 96 |
|
|
2017
Q4 | $338K | Hold |
900
| – | – | 0.07% | 96 |
|
|
2017
Q3 | $402K | Hold |
900
| – | – | 0.08% | 89 |
|
|
2017
Q2 | $442K | Sell |
900
-50
| -5% | -$21.9K | 0.09% | 91 |
|
|
2017
Q1 | $368K | Hold |
950
| – | – | 0.08% | 98 |
|
|
2016
Q4 | $349K | Buy |
950
+50
| +6% | +$19K | 0.07% | 103 |
|
|
2016
Q3 | $362K | Sell |
900
-100
| -10% | -$40.1K | 0.07% | 100 |
|
|
2016
Q2 | $349K | Hold |
1,000
| – | – | 0.07% | 101 |
|
|
2016
Q1 | $360K | Sell |
1,000
-41
| -4% | -$16.9K | 0.08% | 90 |
|
|
2015
Q4 | $565K | Sell |
1,041
-10
| -1% | -$5.42K | 0.12% | 95 |
|
|
2015
Q3 | $489K | Sell |
1,051
-110
| -9% | -$59.1K | 0.12% | 95 |
|
|
2015
Q2 | $592K | Sell |
1,161
-90
| -7% | -$43.9K | 0.11% | 110 |
|
|
2015
Q1 | $565K | Hold |
1,251
| – | – | 0.11% | 109 |
|
|
2014
Q4 | $513K | Sell |
1,251
-14
| -1% | -$5.51K | 0.1% | 116 |
|
|
2014
Q3 | $456K | Hold |
1,265
| – | – | 0.09% | 122 |
|
|
2014
Q2 | $357K | Hold |
1,265
| – | – | 0.07% | 129 |
|
|
2014
Q1 | $380K | Sell |
1,265
-100
| -7% | -$30.8K | 0.07% | 124 |
|
|
2013
Q4 | $376K | Sell |
1,365
-200
| -13% | -$57.5K | 0.07% | 128 |
|
|
2013
Q3 | $490K | Sell |
1,565
-50
| -3% | -$13.2K | 0.1% | 127 |
|
|
2013
Q2 | $363K | Buy |
+1,615
| New | +$376K | 0.08% | 134 |
|
Other funds holding REGN
VCM
N
John G. Ullman & Associates's REGN Position: Q1 2026 in Review
John G. Ullman & Associates reduced its Regeneron Pharmaceuticals (REGN) stake by 50% in Q1 2026, selling an estimated $704K and leaving 910 shares worth $703K. The position accounts for 0.09% of the portfolio, ranked #118.
John G. Ullman & Associates first reported a position in REGN in Q2 2013 and has held it in 45 quarters since. The position peaked at $4.08M in Q1 2025. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.
- John G. Ullman & Associates held 910 shares of Regeneron Pharmaceuticals worth $703K as of Q1 2026.
- John G. Ullman & Associates sold 920 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $704K.
- Regeneron Pharmaceuticals made up 0.09% of John G. Ullman & Associates's portfolio in Q1 2026, its #118 holding.
- John G. Ullman & Associates first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 45 quarters since.
- John G. Ullman & Associates's Regeneron Pharmaceuticals position peaked at $4.08M in Q1 2025.
- 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.
Based on John G. Ullman & Associates's 13F filing for Q1 2026, filed 6 May 2026.